Daniel A. Ollendorf

Best Publications

• Medication Compliance and Persistence: Terminology and Definitions

  Joyce A. Cramer;Anuja Roy;Anita Burrell;Carol J. Fairchild

  2885
  Citations

• Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

  Dhruv S. Kazi;Andrew E. Moran;Pamela G. Coxson;Joanne Penko

  415
  Citations

• Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis

  Julia H. Hayes;Daniel A. Ollendorf;Steven D. Pearson;Michael J. Barry

  274
  Citations

• Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.

  David D. Kim;David D. Kim;Madison C. Silver;Natalia Kunst;Natalia Kunst;Joshua T. Cohen;Joshua T. Cohen

  243
  Citations

• Potential Economic Benefits of Lower-Extremity Amputation Prevention Strategies in Diabetes

  Daniel A Ollendorf;James G Kotsanos;William J Wishner;Mark Friedman

  199
  Citations

• Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients

  Daniel A. Ollendorf;Montserrat Vera-Llonch;Gerry Oster

  175
  Citations

• Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

  Dhruv S. Kazi;Joanne Penko;Pamela G. Coxson;Andrew E. Moran

  169
  Citations

• Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population

  Harinder S. Chahal;Elliot A. Marseille;Jeffrey A. Tice;Steve D. Pearson

  163
  Citations

• Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer: A Cost-Effectiveness Analysis

  Julia H. Hayes;Daniel A. Ollendorf;Steven D. Pearson;Michael J. Barry

  148
  Citations

• Identifying the Need for Good Practices in Health Technology Assessment : Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA

  Finn Børlum Kristensen;Don Husereau;Don Husereau;Mirjana Huić;Michael Drummond

  127
  Citations

• End-stage renal disease-associated managed care costs among patients with and without diabetes.

  Amie T. Joyce;John M. Iacoviello;Soma Nag;Shiva Sajjan

  109
  Citations

• Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.

  Sumeyye Samur;Matthew Klebanoff;Reiner Banken;Daniel S. Pratt

  103
  Citations

• Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population

  Daniel A. Ollendorf;David Klingman;Elisabeth Hazard;Saurabh Ray

  101
  Citations

• Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers

  Daniel A. Ollendorf;Richard H. Chapman;Steven D. Pearson

  98
  Citations

• Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Jeffrey A. Tice

  95
  Citations

• Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction

  Alexander T Sandhu;Daniel A Ollendorf;Richard H Chapman;Steven D Pearson

  89
  Citations

• An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia

  Libby Black;Michael James Naslund;Thomas D. Gilbert;E. Anne Davis

  83
  Citations

• Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Varun M. Kumar

  81
  Citations

• Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

  Melanie D Whittington;R Brett McQueen;Daniel A Ollendorf;Varun M Kumar

  77
  Citations

• Economic Consequences of Venous Thromboembolism Following Major Orthopedic Surgery

  Gerry Oster;Daniel A Ollendorf;Montserrat Vera-Llonch;May Hagiwara

  70
  Citations